The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Johan Lochen, Erik Penser Bank. Phone: +46 8 463 80 00. Erik Penser Bank equity research

Felicia Rittemar, Vator Securities, Phone: +46 8 5333 2737. Vator Securities equity research

Annual Report

  December 22, 2020

Company Presentation

CEO Comments

Read More
  Quarterly Report 1 20/21, January 20, 2021

Dear Shareholders and readers

Following the announcement of the topline results from the phase IIb trial DIAGNODE-2 with Diamyd® in September 2020, we have focused on additional data analyses, manufacturing activities and regulatory activities to take Diamyd® and the company to the next level.
The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
Ulf Hannelius, President and CEO

Calendar

  
February 10 − February 11, 2021
Swiss Nordic Bio 2021
March 31, 2021
Quarterly Report II
Quarterly Report 2 2020/2021
June 23, 2021
Quarterly Report III
Quarterly Report 3 2020/2021
October 6, 2021
Year-End Report
Year-End Report 2020/2021
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of December 30, 2020

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 234 911 13.35 10.02
Essen-Möller, Anders 2 556 223 6 333 040 12.85 34.60
Lindkvist, Bertil 6 240 000 9.02 6.77
Nordnet Pension 2 157 216 3.12 2.34
Swedbank Försäkring 736 710 1.07 0.80
Konstruktions o Försäljningsaktiebolag 725 000 1.05 0.79
Arandi Development AB 512 000 0.74 0.56
Relbo AB 475 550 0.69 0.52
Lindberg, Mikael 460 021 0.67 0.50
Schelé, Sven 435 000 0.63 0.47
Remaining shareholders 39 304 125 56.82 42.64
Total 2 556 223 66 613 573 100.0 100.0

Order GAD for preclinical research

ORDER

Annual Report

  December 22, 2020
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research